BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15492288)

  • 1. 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.
    Oduwole OO; Li Y; Isomaa VV; Mäntyniemi A; Pulkka AE; Soini Y; Vihko PT
    Cancer Res; 2004 Oct; 64(20):7604-9. PubMed ID: 15492288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
    Jansson AK; Gunnarsson C; Cohen M; Sivik T; Stål O
    Cancer Res; 2006 Dec; 66(23):11471-7. PubMed ID: 17145895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
    Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K
    Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzymes as modulators in malignant transformation.
    Vihko P; Herrala A; Härkönen P; Isomaa V; Kaija H; Kurkela R; Li Y; Patrikainen L; Pulkka A; Soronen P; Törn S
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):277-83. PubMed ID: 15860271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of COX-2 and steroid converting enzymes in breast cancer.
    Gunnarsson C; Jansson A; Holmlund B; Ferraud L; Nordenskjöld B; Rutqvist LE; Skoog L; Stål O
    Oncol Rep; 2006 Aug; 16(2):219-24. PubMed ID: 16820896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.
    Gunnarsson C; Olsson BM; Stål O;
    Cancer Res; 2001 Dec; 61(23):8448-51. PubMed ID: 11731426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers.
    Rosa FE; Caldeira JR; Felipes J; Bertonha FB; Quevedo FC; Domingues MA; Moraes Neto FA; Rogatto SR
    Hum Pathol; 2008 May; 39(5):720-30. PubMed ID: 18234277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction.
    Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S
    Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer.
    Kawai H; Ishii A; Washiya K; Konno T; Kon H; Yamaya C; Ono I; Minamiya Y; Ogawa J
    Clin Cancer Res; 2005 Jul; 11(14):5084-9. PubMed ID: 16033821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
    Miyoshi Y; Ando A; Hasegawa S; Ishitobi M; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2003 Jun; 9(6):2288-93. PubMed ID: 12796397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
    Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
    Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
    Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
    Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of 3beta-hydroxysteroid dehydrogenase type 1, P450 aromatase, and 17beta-hydroxysteroid dehydrogenase types 1, 2, 5 and 7 mRNAs in human early and mid-gestation placentas.
    Li Y; Isomaa V; Pulkka A; Herva R; Peltoketo H; Vihko P
    Placenta; 2005 May; 26(5):387-92. PubMed ID: 15850643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients.
    Yaal-Hahoshen N; Shina S; Leider-Trejo L; Barnea I; Shabtai EL; Azenshtein E; Greenberg I; Keydar I; Ben-Baruch A
    Clin Cancer Res; 2006 Aug; 12(15):4474-80. PubMed ID: 16899591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
    Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
    Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of cell proliferation by steroids: the role of 17HSDs.
    Vihko P; Herrala A; Härkönen P; Isomaa V; Kaija H; Kurkela R; Pulkka A
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):141-8. PubMed ID: 16406264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.